IMP:pyrophosphate phosphoribosyltransferase (IPPase) (EC 2.4.2.8) has been purified over 7000-fold from human erythrocytes. The purified enzyme moved as a single band on disc electrophoresis. Antisera prepared in rabbits and rats against the purified enzyme precipitated and neutralized the enzyme, but had no effect on AMP-pyrophosphate phosphoribosyltransferase (EC 2.4 In Lesch-Nyhan (LN) disease (10), the activity of the enzyme IMP:pyrophosphate phosphoribosyltransferase [recommended trivial name, IMP pyrophosphorylase, here abbreviated IPPase; identical with hypoxanthine (guanine) phosphoribosyltransferase, EC 2.4.2.8] is operationally absent (1). It is not known whether phenotypic expression is due to lack of synthesis of enzyme, or whether the enzyme is synthesized but is structurally ineffective. In view of the importance of the enzyme in human neurochemistry, as evidenced by the severity of symptoms when it is absent, it would be desirable to have purified enzyme available, and to determine whether a modified form is produced in patients.
disease reacted with antisera against normal IPPase. Lysates from LN erythrocytes blocked the inactivation of normal enzyme by the antibody. LN erythrocytes had about the same concentration of enzyme protein as normal erythrocytes.
The genetic defect in LN results in the production of essentially normal amounts of an immunologically identifiable but catalytically incompetent enzyme. Thus LN is apparently the result of a mutation in a structural gene and is not due to deletion of a structural gene or defect in a regulatory gene.
In Lesch-Nyhan (LN) disease (10) , the activity of the enzyme IMP:pyrophosphate phosphoribosyltransferase [recommended trivial name, IMP pyrophosphorylase, here abbreviated IPPase; identical with hypoxanthine (guanine) phosphoribosyltransferase, EC 2.4.2.8] is operationally absent (1) . It is not known whether phenotypic expression is due to lack of synthesis of enzyme, or whether the enzyme is synthesized but is structurally ineffective. In view of the importance of the enzyme in human neurochemistry, as evidenced by the severity of symptoms when it is absent, it would be desirable to have purified enzyme available, and to determine whether a modified form is produced in patients.
We have approached this question using immunological techniques. A highly purified IPPase has been isolated from normal human erythrocytes, and antibodies to it have been prepared in the rat and rabbit. The antisera have been used to test for the presence of an altered IPPase in extracts of erythrocytes of five patients with LN disease. 
MATERIALS AND METHODS

Enzyme purification
Removal of Hemoglobin (Hb). Hb was removed by the method of Hennessey et al. (2) . Outdated erythrocytes (N.Y. Blood Center), 300 ml, were lysed by freezing and thawing and diluted with 0.67 vol of 0.01 M potassium phosphate buffer (K-PO4), pH 7.0. Stroma was removed by centrifugation, and 20 g of DEAE-cellulose (Cellex D, 0.65 meq/g, BioRad) , previously equilibrated in 0.01 M K-PO4, pH 7.0, was added and slowly stirred for 1 hr. The DEAE-cellulose was collected by filtration, and the dark red filtrate was discarded. Residual Hb was rinsed out of the cellulose by repeated washings with 0.01 M K-PO4 (pH 7.0) until a clear colorless filtrate was observed. The DEAE-cellulose was suspended in 400 ml of 0.01 M K-PO4 (pH 7.4)-0.2 M KCl-0.001 M 2-mercaptoethanol, stirred for 1 hr, collected by filtration, and rinsed with an additional 200 ml of 0.01 M K-PO4-0.2 M KC1-0.001 M mercaptoethanol. The rinse was then combined with the first filtrate. This eluate could be frozen and stored at -20°C without significant loss of enzyme activity.
Salt Fractionation. Solid ammonium sulfate (Schwarz BioResearch, special enzyme grade) was added to the DEAEcellulose eluate to a final concentration of 27.4 g/100 ml (47% saturation). 6 ml of concentrated NH40H was added per liter of eluate to maintain the pH in the range of 7-8. Precipitation was allowed to proceed overnight. The protein that was collected by centrifugation at 10,000 X g for 40 min was discarded. The supernatant was then brought to 70% saturation by the addition of further ammonium sulfate (14.5 g/100 ml). Precipitation was complete within 5 hr and the protein was collected by centrifugation at 10,000 X g for 40 min. The supernatant was discarded and the precipitate was dissolved in a minimal volume of 0.01 M K-PO4 (pH 6.4)-0.001 M 2-mercaptoethanol.
Removal of Heat-Labile Proteins. The 47-70% fraction was concentrated in dialysis tubing by packing in aquacide II (MW 250,000, Calbiochem) to a final concentration of 20-30 mg/ml. This solution was placed in an Erlenmeyer flask and immersed in a 68°C water-bath. The sample was allowed to remain in the bath for 3 min after it reached 60°C. Precipitated protein was removed by centrifugation at 15,000 X g and discarded; IPPase, which is heat-stable, remained in the supernate. DEAE-Cellulose Column I. 15 ml of the supernate after heat treatment, containing 350-700 mg protein, was exhaustively dialyzed against 0.01 M K-PO4 (pH 6.4)-0.001 M 2-mercaptoethanol by means of a Crowe-Englander (3) microdialyzer with five changes of buffer. This solution was then applied to a 2.5 X 35 cm DEAE-cellulose column (0.9 meq/g) previously equilibrated with 0.01 M K-PO4 (pH 6.4)-0.001 M 2-mercaptoethanol. Ascending chromatography in a linear gradient of 0.01-0.12 M K-PO4 (pH 6.4), with 0.001 M 2-mercaptoethanol present throughout, was performed at a flow rate of 30-50 ml/hr. Fractions with the highest specific activity were pooled, made 0.1 mM with respect to EDTA, and concentrated in dialysis tubing with aquacide II.
Sephadex G-150 Chromatography. The enzyme solution was dialyzed against 0.01 M Tris HCl, (pH 7.4)-0.1 M KCl-0.001 M mercaptoethanol. Then 10 ml of it, containing 80-160 mg protein, was applied to a 2.5 X 87 cm Sephadex G-150 column equilibrated with the dialysis buffer. Ascending gel filtration was performed at a rate of 9 ml/hr, and 6-ml fractions were collected. Fractions with maximum specific activity were pooled and concentrated in aquacide. EDTA was again employed to stabilize the enzyme. DEAE-Cellulose Column I. Concentrated enzyme preparation was dialyzed against 0.01 M K-PO4 (pH 7.0)-0.01 M KCl-0.001 M mercaptoethanol, and then applied to a 0.9 X 45 cm DEAE-cellulose (1.0 meq/g, Sigma) column equilibrated with the same buffer. Enzyme was eluted with a linear gradient of KCl from 0.01 to 0.2 M at a flow rate of 10 ml/hr; 5-ml fractions were collected. Highly active fractions were pooled and concentrated in aquacide II.
Polyacrylamide Gel Electrophoresis. Electrophoresis of 10-to 100-uAl samples containing 50-400,ig of protein was performed by the method of Davis (4) protein band was identified by fluorescent staining (5). Gels were removed from their glass tubes and immersed for 2.5 min in 0.1 M K-PO4 (pH 6.8)-0.003% magnesium 1-anilino-8-naphthalene sulfonate (Eastman Organic). The enzyme band was then cut out and eluted by homogenization in 0.01 Ml Tris * HCl, pH 7.4. Enzyme assay A modification (14) of the methods described by Murray (6) and Breitman (7) was used. Aliquots of the reaction mixture were applied as spots to DEAE-cellulose paper and radioactive precursor was removed by washing for 5-10 mim. The papers were then dried, and radioactivity was assayed in a liquid scintillation spectrometer.
The assay was checked by identification of the radioactive product by paper chromatography of the reaction mixture in two systems. Essentially all the label was found in hypoxanthine or inosinic acid. Small amounts of radioactive impurities were detected in purified labeled hypoxanthine. They migrated with the markers for nucleoside and nucleotide. Amounts of contaminants determined in this way were used to correct the assay data.
Preparation of Purified [8-'4C] adenine (10 mg) was dissolved in 5 ml of 1 N HCl and heated on a steam-bath. Four molar equivalents of NaNO2 were added stepwise over a 10-min period and the contents of the flask were then heated for an additional 45 to at 2.5 X 35) cm DEAE-cellhlose column, previously equilibrated with 0.01 M K-PO4 (pH 6.4)-0.001 M 2-mercaptoethanol. Ascending chromatography was performed at a flow rate of 35 ml/hr, and 12.5-ml fraction were collected. Linear gradient is from 0.01 to 0.12 M K-PO4 (0.001 M 2-mereaptoethanol), pH 6.4. normal or LN erythrocytes for 16 hr at 40C. The resulting precipitates were removed by centrifugation, and the supernatant solutions were used in enzyme neutralization assays.
Selection of LN patients
The typical clinical picture (10) was present in four patients. The fifth patient was 11 months old, retarded but not yet self-mutilating. The biochemical evidence in all patients included hyperuricosuria (11) , inverted hypoxanthine/xanthine ratio (12) , absence of erythrocyte IPPase activity (1), and anl elevated AMP:pyrophosphate phosphoribosyltransferase (EC 2.4.2.7) activity in erythrocytes (1, 13) .
RESULTS
Normal erythrocytes were treated as described in Table 1 , and IPPase was thereby purified 7000-fold. The purified enzyme migrated as a single band on gel electrophoresis, moving 1.7 cm in 2.5 hr under a gradient of 33 V/cm. It was stable as a suspension in 85-95% ammonium sulfate at 40C (< 15% loss in 2 weeks). Other properties of the enzyme will be reported elsewhere.
Antisera were produced in the rat and rabbit by injection of the purified preparation. Three lines of precipitation were formed by immunodiffusion of the enzyme against either antiserum. These components have been designated a, b, and c. Component a is the predominant antigen and is readily identified in erythrocyte lysates. Components b and c occur in rather low concentration in erythrocytes, and are difficult to distinguish by immunodiffusion. Immunoelectrophoresis of erythrocyte lysates from normal subjects and LN patients showed that component a has a high electrophoretic mobility, similar to that of serum albumin; components b and c migrated in the region of a and fl globulins respectively. These antisera did not react with human hemoglobin or with normal human serum. When rat and rabbit antisera were both tested against enzyme on Ouchterlony plates, lines of identity were formed, which indicates that antisera prepared in both species detected the same antigens.
In the first purification of IPPase, the elution pattern of the enzyme from DEAE-cellulose was skewed. In a later preparation, two clearly-defined peaks of enzyme activity were obtaimed ( Fig. 1) by the same technique. In this run the second peak was several times as large as that usually seen. In immunodiffusion tests the material in the first peak produced two lines of precipitation corresponding to components a and b, of which component a was the major form. The second peak contained components b and c, but no a. The possibility exists that component a represents an impurity.
The ability of the antiserum to neutralize enzyme activity was investigated by titration of rat anti-IPPase antiglobulin against purified IPPase. A typical parabolic response was seen in passing from antibody excess, with neutralization of over 90% of IPPase activity at the optimal antigen :antibody ratio ( Table 2) .
A neutralization-inhibition test was performed (Table 3) . Rat anti-IPPase antiglobulin and IPPase were used in proportions that produced over 90% neutralization of enzyme activity. When the antiglobulin first reacted with a lysate of LN or normal erythrocytes its neutralizing capacity was removed. This was not due to nonspecific adsorption of antibody by precipitates formed against contaminants; addition of asparaginase and rabbit anti-asparaginase serum produced a considerable precipitate but did not affect the IPPase reaction. Furthermore, supernatant solutions from which all IPPase activity had been removed with antiserum had normal AMP:pyrophosphate phosphoribosyltransferase activity. This indicates that the functionally similar enzymes are antigenically distinct. Similar results were seen with all five LN patients. The fact that lysate corresponding to 3 mg of LN blood could almost completely block the inhibition, by anti-IPPase, of purified IPPase equivalent to about 1.5 mg of blood indicates that significant amounts of antigen are formed in LN and normal cells, which confirms the Ouchterlony studies. DISCUSSION Previous efforts to discern IPPase synthesis in LN patients were limited to measurements of enzyme activity. Some investigators (14) have reported the presence of small amounts of activity, which implied that the deficiency in enzyme synthesis was not complete. In all instances, the evidence for enzyme activity involved the conversion of radioactive sub- strate to radioactive products. The small amounts of conversion reported in LN subjects would require rigorous proof of substrate purity and of identification of product. These criteria have not been met sufficiently well to be convincing.
In one patient with LN (15), high concentrations of 5-phosphoribosyl-1-pyrophosphate (PRPP) enhanced IPPase activity in vitro. This strongly suggests that in this patient the enzyme synthesized is altered in its ability to react with normal concentrations of PRPP. Four additional patients studied by the same authors and all of five cases reported here did not demonstrate this modification in enzyme kinetics. The reported case may, therefore, represent a rather rare type of mutation.
We have used an immunological approach to examine possible IPPase synthesis in LN. The results in all five patients studied are quite conclusive. A protein is synthesized, in essentially normal amounts, which is identifiable immunologically as IPPase but which lacks catalytic activity. At first sight it would seem desirable to extend the series, but it appears from experience with other inborn errors of metabolism (such as the hemoglobinopathies) that structural defects in enzymes are common and probably heterogeneous, as is indicated for this disease at least by the one case that responded to excesses of PRPP. These studies have clearly established the existence of multiple allelic variants in man. In the course of purification of IPPase it became evident that the human erythrocyte enzyme exists in at least two distinct forms, separable by ion-exchange chromatography.
Because the amount of (inactive) enzyme in LN patients was approximately the same as in normal subjects, so that the inactive protein is presumably formed at about the same rate as is the normal enzyme, the defect of LN is probably not due to changes in a regulatory gene or to deletion of a structural gene. It seems most likely that it is the result of a change in a structural gene.
Enzyme concentration in a cell is ultimately dependent on the relative rates of synthesis and degradation. In the mature erythrocyte, protein synthesis has ceased but degradation continues. Nevertheless the fairly normal concentration of inactive IPPase in the LN erythrocyte indicates that its regulation is not controlled by substrate concentration, as has been seen with inducible enzymes. Concentrations of both substrates of IPPase are elevated in LN erythrocytes (16, 12) . De novo synthesis is a major source of IMP and GMP in metabolizing cells, so that product concentration is probably explanation of these observations is that the synthesis and degradation of this defective enzyme are controlled in the same way as that of the normal enzyme. This regulation is independent of feedback and repression, but resembles more the mechanisms envisioned by Schimke et al. (17, 18) , in which there are specific sites that determine enzyme degradation.
